Geron Corporation GERN, a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET.
A live audio webcast of the presentation will be available on Geron's website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company's website for 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005329/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.